TG Therapeutics, Inc. (TGTX)

About TG Therapeutics, Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

Latest reported results

TG Therapeutics Inc. reported revenue of $240.3 million for Q2 FY2026, up 70.3% from the same period a year earlier.

Institutional ownership

In 13F filings for the quarter ended June 30, 2026, 416 institutions reported holding TGTX, with 111.0 million shares worth $6.1 billion in aggregate. The largest reported holders were BlackRock, Vanguard and State Street. Of the 5 largest reported holders, 2 added shares and 3 reduced their positions during the quarter.

More on TGTX

• TGTX sentiment: whether news and social coverage of TG Therapeutics, Inc. leans bullish or bearish, and the stories driving it.
• TGTX ownership: all 416 reporting institutions, plus insider and congressional trades.
• TGTX financials: revenue, net income, operating margin and free cash flow through Q2 FY2026.

SentiSense also tracks daily options readings for TG Therapeutics, Inc.: IV rank, put/call percentile, 25-delta skew and open-interest walls.

Frequently asked questions